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There are significant associations between possession of certain
HLA class I alleles and rate of progression to AIDS. Immunological
data provide an explanatory mechanism for this relationship.
Patients with HLA types associated with rapid disease progression
recognize a significantly smaller fraction of their known repertoire
of viral epitopes than do patients with HLA types associated with
slow progression. Population frequency of HLA types (or super-
types) and their capacity to elicit cytotoxic T lymphocyte responses
are also negatively correlated. These data provide an immunolog-
ical mechanism to explain HLA-related risk of progression to AIDS
and emphasize the central role of viral evolution in the pathogen-
esis of HIV.
Why is it that, after infection with HIV, some peoplebecome ill quite rapidly while others remain well for more
than a decade? Despite 20 years of fruitful research into HIV
and AIDS (1), this simple question remains unanswered. It is
clear that the length of the asymptomatic period is determined,
in some way, through the interaction of the infecting virus and
the immune response of the host. This understanding is solidly
underpinned by two long-standing observations. First, patients
with higher viral loads progress to disease more quickly (2, 3).
Second, the possession of certain human leukocyte antigen
(HLA) class I molecules (e.g., HLA B35) predisposes patients to
rapid disease progression, whereas others (e.g., HLA B27 and
HLA B58) endow them with a longer asymptomatic period
(4–9).
HLA class I molecules are present on the surface of all
nucleated cells where they present short viral peptide fragments,
called epitopes, that elicit immune responses from cytotoxic T
lymphocytes (CTLs). Each HLA class I molecule is able to
present only a limited range of peptides. The HLA class I
genotype of a patient therefore dictates the repertoire of CTL
responses he or she is able to mount, which translates into
different abilities to cope with an HIV infection. Patients who
are heterozygous for their HLA class I molecules are at a
significant advantage if infected with HIV, implying that the
quantity and breadth of the immune response determines the
success or failure of viral control (4). However, counts of
HIV-specific CTLs cannot be simply correlated with viral load
or viral clearance rate (10), in contrast to earlier reports (11).
This lack of correlation between virus load and HIV-specific
CTLs implies that other characteristics of the cellular immune
response, not only its quantity, underlie the relationship between
HLA class I alleles and HIV control. The present study sheds
light on this controversy by explaining the association between
HLA alleles and HIV disease progression through quantifiable
CTL function.
HLA class I alleles can be reclassified into nine major super-
types based on their peptide-binding properties (12). Under this
classification, the HLA supertype of an individual is highly
predictive of his or her viral load (13). Furthermore, this
classification scheme reveals a rare allele advantage, because less
common HLA supertypes (HLA B58s and HLA B62s) are
associated with the lowest viral loads, whereas more common
HLA supertypes (HLA A2s and HLA B7s) are associated with
higher viral loads.
Why should rare alleles be advantageous? A hallmark of HIV
infection is its ability to generate immune escape mutations in
epitopes (14–17) and their f lanking regions (18, 19). CTL escape
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mutants have been found in population studies, in which they
correlate with higher viral loads (20), and they can be transmit-
ted from mother to child (21, 22) as well as between sexual
partners (ref. 18 and C. Edwards, H. T. Zhang, and A. Milicic,
personal communication). Escape mutations tend to be main-
tained after transmission into a new host who shares the
restricting HLA molecule. Reversion has been described after
HIV is transmitted to a new host in whom there is HLA
mismatch (18, 23). However, the extent to which escape muta-
tions revert to wild-type sequence will depend on the fitness cost
of the escape mutation (23, 24). The accumulation of transmitted
immune escape mutants probably explains the relative paucity of
epitope regions in more variable parts of the HIV genome (25).
Therefore, having rare HLA alleles is advantageous, because
such individuals are less likely to be infected with HIV that is
preadapted to the CTL responses they can make.
Hence, two questions arise. One, do HLA alleles associated
with slow disease progression elicit detectable CTL responses in
a higher proportion of patients than HLA alleles associated with
rapid disease progression? Two, do rare HLA alleles elicit CTL
responses in a greater proportion of patients than more common
HLA types? These have to be treated as two separate questions
because, for classically defined HLA types, there is no significant
relationship between relative hazard and population frequency.
The results of Trachtenberg et al. (13) raise a third question: Do
rare HLA supertypes elicit CTL responses in a greater propor-
tion of patients than more common HLA supertypes? We
present data and simple regression analyses to answer these
three questions.
Materials and Methods
Patient Cohort. The Swiss-Spanish Intermittent Therapy Trial was
a large study of structured treatment interruptions that assessed
the clinical, virological, and immunological outcome of planned
short breaks in the chemotherapeutic regimen of chronically
HIV-infected patients. The study yielded cross-sectional and
longitudinal data on CTL responses detected by IFN- enzyme-
linked immunospot assays in 84 patients followed for an av-
erage of 14 months (range, 3–19 months) (Table 1). The patient
group is described in detail elsewhere (26), as are the dynamics
of the breadth and magnitude of their CTL responses and viral
loads (10, 27).
Epitopes Tested. Each patient was HLA-typed and tested repeat-
edly (mean number of times tested, 16; range, 3–26) to assess the
frequency of responsive HIV-specific CTLs in their peripheral
blood lymphocytes. Patients were tested for CTL responses with
synthetic peptides corresponding to previously described HLA
class I-restricted optimal HIV CTL epitopes. The epitopes tested
are described in the Los Alamos database (www.hiv.lanl.gov
contentimmunologytablesctlsummary.html) in the context
of HIV infection and are listed in Table 2, which is published as
supporting information on the PNAS web site.
Because the HLA class I type of a patient determines the
repertoire of known epitopes they might be expected to recog-
nize, their cells were tested against a panel of peptide epitopes
designed to match their individual HLA type (median number
tested, 16; range, 2–31).
Relative Hazards of Disease Progression. Because large patient
cohorts are needed to establish genetic associations and the
patients in this study were given potent antiretroviral treatment,
we could not derive relative hazards of disease progression from
this data set. Instead, we used the relative hazards as calculated
by O’Brien et al. (8) for a large cohort of HIV-infected white
patients. The full list of relative hazards for the O’Brien et al.
cohorts can be accessed at http:home.ncifcrf.govccrlgd
datatablesgao101.htm. Population HLA frequencies for class I
A and B alleles are very highly correlated between the Swiss and
U.S. white patients (  0.99 and 0.97, respectively) (28, 29).
Statistical Analysis. Data were analyzed by using MINITAB statis-
tical software [release 13, Minitab Statistical Software, State
College, PA (2000)].
Weighted Regressions. In a weighted least-squares regression, the
weighted error sum of squares,

i
w iY i  Yˆ2,
is minimized (wi are the weights). In this context, the result is to
deemphasize the HLAs for which we fear we are missing most
information: those with few known epitopes. An alternative
strategy, just excluding the HLAs tested with only one epitope,
gives similar results.
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Table 1. Details of the cohort recruited to the Swiss–Spanish
Intermittent Therapy Trial (SSITT)
No. of patients recruited to SSITT 133
No. of patients analyzed in this study* 84
Sex (malefemale) 5232
Details of therapy
No. of patients on dual therapy 9
No. of patients on triple therapy 75
Patient age,† years 40 (22–68)
Therapy duration,† days 808 (254–1,337)
VL undetectable duration,† days 707 (187–1,285)
CD4 pre-therapy,† cells per l 359 (1–1,035)
Viral load pre-therapy,† log10 RNA copies per ml 4.41 (2.23–6.11)
*Immune responses were measured for 97 patients. Twelve patients were
excluded because they had no immune responses detected at any time point
measured, and one patient was excluded because he had excessive responses
for most peptides measured, leaving 84 patients in the data set.
†Data are median values, with the ranges shown in parentheses.
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Lack of Independence. The plots of relative hazard and HLA
frequency against HLA capacity to elicit CTL responses are
intuitively appealing but suffer from some lack of independence.
Most patients contribute to more than one data point, because
they bear several HLA alleles. The degree of correlation be-
tween HLA capacities to elicit CTL responses for a given patient
varies widely across the six different pairwise comparisons, and
none of the estimated correlation coefficients are significantly
Fig. 1. HLA capacity to elicit CTL responses for all of the 22 different class I alleles tested in this cohort. HLA type and number of patients bearing that HLA type
are indicated in the individual plots. Bars represent the fraction of all patients bearing that allele who ever, during the study, mounted a detectable CTL response
to the optimal peptide indicated below the axis. The three-letter code indicates the first three amino acids of the peptide sequence (see Table 2). The horizontal
lines spanning each plot are the average fraction responding across all epitopes tested for that allele. This value is the HLA capacity to elicit CTL responses, defined
as the proportion of all possible patientepitope combinations (for that HLA type) that ever elicit a response in patients bearing the appropriate HLA type. Alleles
are ordered in terms of rising capacity to elicit CTL responses.
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different from zero. To explore the impact of correlations
between patients’ individual HLA capacities to elicit CTL re-
sponses, we performed a randomization test. The data were
subsampled such that each patient only contributed to the
calculation of one HLA capacity to elicit CTL responses. This
sampling of just one quarter of the information gathered was
performed 100 times, new HLA capacities to elicit CTL re-
sponses were calculated, and the regressions shown in Fig. 2 were
repeated. Both relationships were maintained under this very
uncompromising test; the median P value for the relationship
with relative hazard was P  0.013, and for the relationship with
HLA frequency the median P value was P  0.031.
Alternative Analyses. Our weighting scheme acts to acknowledge
lack of confidence in the estimated capacity to elicit CTL
responses for HLAs tested with few epitopes. An alternative
strategy is to compare only the maximally targeted epitopes for
each HLA (i.e., GEI for B8, EVI for A26, etc.) Under such a
comparison, the relationship between relative hazard and max-
imum targeting frequency holds (R2  26%; P  0.015). As one
would expect from the relationship between number of epitopes
tested and HLA allelic frequency (positive relationship, P 
0.04), the use of the maximum destroys the relationship between
allelic frequency and targeting frequency (R2  2%; P  0.5).
Results
We wished to know whether a patient with a particular HLA
class I molecule could recognize known peptide antigens derived
from the subtype B consensus sequence. For example, if a patient
was found to bear HLA A2, peptide numbers 29–37 of Table 2
were tested in T cell assays (IFN- enzyme-linked immunospot
assays) by using the patient’s own peripheral blood lymphocytes
(26). If that patient ever recognized one of those consensus
peptide antigens, we scored the result as positive for that peptide.
For each of 84 patients taking part in a study of structured
therapy interruptions, this exercise was repeated at many time
points (mean number of times tested, 16; range; 3–26) by using
the relevant epitopes from the panel of peptides shown in Table
2. We used this optimal peptide approach so that when we
detected a response, we could identify the restricting HLA. The
use of overlapping peptide libraries would not have permitted
such identification.
Many of the responses patients should be able to make given
their HLA restriction are nevertheless absent: only one peptide
(KAF restricted by B57) elicited responses in all patients with
that allele (Fig. 1). HLA molecules vary greatly in their capacity
to elicit responses to peptides. In what follows we explore
patterns in that variability in capacity to elicit CTL responses.
The capacity of a given HLA allele to elicit a detectable
anti-HIV response can be defined as the average frequency with
which optimal epitopes, restricted to a particular HLA allele,
elicit responses in patients carrying that allele. This frequency is
a measure of the area under the curve shown in the bar charts
in Fig. 1, adjusted for the number of epitopes tested, and is
indicated with the horizontal line spanning each graph. For
example, five optimal peptides restricted by B27 were tested in
the nine patients bearing B27. Thus, there were 45 possible
combinations for B27 to score as positive. Twenty-three positives
were found, giving a capacity to elicit CTL responses of 51% for
HLA B27.
To answer the first question (do ‘‘slow-progressor’’ HLA class
I alleles elicit CTL responses to the peptides they restrict in a
large proportion of the patients bearing that allele?), we per-
formed a weighted linear regression with the number of peptides
tested as the weights. The regression yields a highly significant
negative relationship between the relative hazard of disease
progression and the ability of the different HLAs to elicit a CTL
response (Fig. 2A).
To answer the second question (do rare HLA class I alleles
elicit CTL responses to the peptides they restrict in a large
proportion of patients bearing those alleles?), we performed a
weighted regression of HLA allelic frequency in this cohort
against the ability of the different HLAs to elicit a CTL response
with the number of peptides tested as the weights (Fig. 2B). Rare
alleles elicit responses to a larger proportion of the known
potential antigens as compared with common alleles. This
relationship is also significant if Swiss-population HLA frequen-
cies are used (R2  29%; P  0.03).
To answer the third question (do rare HLA supertypes have
a high capacity to elicit CTL responses?), we performed a linear
regression (Fig. 3). The result was a significant negative rela-
tionship; patients bearing rare HLA supertypes have a higher
probability of recognizing known optimal peptides restricted by
the HLAs in that supertype.
Could these results be artifacts of the fact that we do not know
all of the CTL epitopes of HIV? Overall, more optimal epitopes
are known for common HLA types than for rare ones (P 0.04).
However, the number of optimal epitopes and the capacity of
each HLA to elicit CTL responses do not correlate. Notice how
Fig. 2. Both slowly progressing and rare class I alleles elicit CTL responses in
a large proportion of patients bearing those alleles. (A) Class I-related relative
hazard of disease progression is negatively correlated with HLA capacity to
elicit CTL responses. In a weighted regression, the slope is highly significantly
less than zero. (B) HLA allelic frequency in the cohort is negatively correlated
with HLA capacity to elicit CTL responses. In a weighted regression, the slope
is highly significantly less than zero. In both regression analyses the numbers
of epitopes tested for each class I allele were used as weights in the regression,
reflecting greater confidence in an average taken across many epitopes than
across few (26).
Scherer et al. PNAS  August 17, 2004  vol. 101  no. 33  12269
M
ED
IC
A
L
SC
IE
N
CE
S
the seven HLA types for which only one epitope was tested are
scattered through Fig. 1. We weighted the regression analyses
with the number of epitopes, thereby incorporating the fact that
HLA alleles for which more epitopes are known have higher
information content than those for which fewer epitopes are
known (26).
We used a simple but robust measure of CTL function and
compared it with the risk of disease progression across a large
range of HLA types. Because the CTL assay was performed by
using optimal peptides, absent responses may reflect the im-
mense sequence variability characteristic of HIV. In agreement
with Trachtenberg et al. (13), we would argue that patients with
‘‘rapid-progressor’’ class I alleles recognize a small proportion of
their known repertoire because their infecting HIV carries a
large number of CTL escape mutations relevant to the responses
they might mount. This hypothesis is supported by our findings
of an association between HLA frequency and immune re-
sponse, because viral adaptation is likely to be influenced
predominantly by the most common, HLA-dictated immune
pressures. Widespread, transmitted immune selection would be
expected to drive an increase in viral virulence as the virus
adapts to the most common types of hosts. The fact that no such
shift in the virulence of HIV has been observed is enigmatic.
The associations observed between HLA class I alleles and
time to progression to AIDS have long suggested a link between
immune response and the ability to delay the onset of disease.
Other arms of the immune response such as HLA class II-
restricted T cells and humoral responses are also implicated in
the control of infection. Recent evidence on viral mutations and
population frequency of HLA alleles has supported this link
without directly assessing the immune response, which provides
the most plausible mechanistic explanation for these assertions
(13, 20).
We have shown that CTL responses measured in patients with
HLA alleles associated with rapid progression recognize only a
small proportion of the known epitopes restricted by these HLA
class I molecules. Conversely, CTL responses measured in
patients with slow-progressor HLA alleles recognize a large
proportion of the known mapped epitopes. These data provide
a coherent immunological mechanism that explains HLA-
related risk of disease progression in a model that links host
genotype, host immune function, and viral evolution.
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Fig. 3. The frequency of HLA supertypes within the cohort is negatively
correlated with the supertype capacity to elicit CTL responses. High-resolution
HLA typing was used to classify 284 of the 336 possible patient HLA alleles into
nine supertypes according to the guidelines suggested by Sette and Sidney
(12). Of the 88 optimal peptides (listed in Table 2), 58 had the structural motifs
compatible with allocation to their respective supertype (12) and were sub-
sequently used in the analysis. For each of the nine supertypes, the sum of the
possible patientepitope combinations for each constituent HLA type was
calculated. The proportion of these combinations that ever elicited a response
was calculated and defined as the supertype capacity to elicit CTL responses.
For example, in this study, the constituent HLA types for supertype A1 are A1
and A32. Of patients whose supertype was A1, there were seven HLA A32
individuals tested against one epitope and 20 HLA A1 individuals tested
against three epitopes. Therefore, there is a maximum of 67 [(20  3)  (7 
1)] positive responses. Of these, only three responses were recorded by IFN-
enzyme-linked immunospot, giving a supertype capacity to elicit CTL re-
sponses of 3 of 67 (4.48%). This regression is unweighted, because there is no
simple equivalent of the number of epitopes tested.
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